Erythropoietin (EPO) is a glycoprotein cytokine secreted by the kidney in response to cellular hypoxia. EPO binds to the erythropoietin receptor on the red cell progenitor surface and activates a JAK2 signalling cascade. This initiates the STAT5, PIK3 and Ras MAPK pathways. This results in differentiation, survival and proliferation of the erythroid cell.
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Purity||≥95%, Endotoxin ≤0.01EU/ug|
|Storage||2-8°C, dry, protect from light, sealed|
Shared and unique determinants of the erythropoietin (EPO) receptor are important for binding EPO and EPO mimetic peptide.
Middleton SA, et al. J Biol Chem. 1999 May 14;274(20):14163-9. PMID: 10318834.
An antagonist peptide-EPO receptor complex suggests that receptor dimerization is not sufficient for activation.
Livnah O, et al. Nat Struct Biol. 1998 Nov;5(11):993-1004. PMID: 9808045.
|Related Cytokines Products|
|Recombinant Human Endostatin
Recombinant Human Endostatin is an endogenous antiangiogenic peptide with multiple antitumor roles through modulation of various receptors in the plasma membrane, such as suppression of angiogenesis and inhibition of tumor-cell migration and invasion.
|Recombinant Human EGF
Recombinant Human EGF
|Recombinant Human VEGF165
Recombinant Human VEGF165
|Recombinant Human bFGF
Recombinant Human bFGF
|Recombinant Human PDGF-BB
Recombinant Human PDGF-BB
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.